Cannabics Pharmaceuticals to Co-Sponsor the Canada Cannabis House at the World Economic Forum in Davos
TEL AVIV, Israel and BETHESDA, Maryland, Jan. 22, 2019 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (CNBX), a leader in personalized cannabinoid medicine focused on cancer and its side effects, announced that Mr. Eyal Barad, Co-Founder and CEO, and Dr. Eyal Ballan, Co-Founder and CTO, will be in Davos, Switzerland in January, 2019. They will attend the World Economic Conference as part of the CannaTech Davos at Canada Cannabis House Pavilion, hosted in collaboration with the Canadian Securities Exchange and OTC Markets.
Cannabics CEO Eyal Barad will be featured in the panel "Exporting Cannabis Innovation to the World from Israel" Forum, on Thursday January 24th, from 4:00pm to 6:00pm.
"We are pleased to be attending an event of this global scale, which affords us the opportunity of presenting our technology one on one to world leaders and the most highly respected group of political, NGO and business executives", said Mr. Eyal Barad. "We hope to be able to leverage our participation in the Forum to bring to light the importance of Cannabis both economically and therapeutically and continue our mission of bringing Cannabinoid based therapies to regulated modern medicine."
The Canada Cannabis House will feature sessions with distinguished group of speakers, including Mr. Ehud Barak, Former Israeli Prime Minister and Chairman of InterCure; as well as Mr. Roei Zerahia, CEO of Canndoc; Mr. Yona Levy, CEO of Alvit and Tefen; Mr. Lorne Gertner, Chairman of Hiku Brands; Mr. Jason Warnock, CEO of TheraCann; and Mr. Saul Kaye, CEO of iCAN, Israel Cannabis.
Saul Kaye noted, "I am thrilled that CannaTech will be co-hosting the Canada Cannabis House along with the Canadian Securities Exchange (CSE), OTC markets, and Kapoor Capital in Davos. It is an honor to participate in Davos and help regulators and industry giants understand the impact of this emerging industry on a global level.
"The emerging cannabis industry is poised to revolutionize patient care, and these changes are creating new global ecosystems poised to have a positive impact with new treatments. Cannabis is part and parcel of the next wave of globalization and a serious discussion in Davos could not be more timely," said iCAN's CEO and Founder, Mr. Saul Kaye.
About CannaTech
CannaTech is the
world's premier medical cannabis event. As a globally renowned
platform for education, innovation, and acceleration, CannaTech
showcases the brightest minds in the cannabis industry. Events are
hosted around the world, offering a unique opportunity to engage
with experts and pioneers in the fields of finance, science,
government policy, ag-tech and more.
About Cannabics
Pharmaceuticals
Headquartered in Tel-Aviv,
Israel, Cannabics Pharmaceuticals Inc. (CNBX) is a U.S
public company that is developing a platform which leverages novel
drug-screening tools and artificial intelligence to create
cannabinoid-based therapies for cancer that are more precise to a
patient's profile. By developing tools to assess effectiveness on a
personalized basis, Cannabics is helping to move cannabinoids into
the future of cancer therapy. The company's R&D is based in
Israel, where it is licensed by the Ministry of Health
to conduct scientific and clinical research on cannabinoid
formulations and Cancer.
For the latest updates on Cannabics Pharmaceuticals follow the company on Twitter @cannabics1, Facebook @CannabicsPharmaceuticals and LinkedIn .
Disclaimer:
Certain statements
contained in this release may constitute forward-looking statements
within the meaning of the Private Securities Litigation Reform Act
of 1995. Such statements include but are not limited to statements
identified by words such as "believes," "expects," "anticipates,"
"estimates," "intends," "plans," "targets," "projects" and similar
expressions. The statements in this release are based upon the
current beliefs and expectations of our company's management and
are subject to significant risks and uncertainties. Actual results
may differ from those set forth in the forward-looking statements.
Numerous factors could cause or contribute to such differences,
including, but not limited to, results of clinical trials and/or
other studies, the challenges inherent in new product development
initiatives, the effect of any competitive products, our ability to
license and protect our intellectual property, our ability to raise
additional capital in the future that is necessary to maintain our
business, changes in government policy and/or regulation, potential
litigation by or against us, any governmental review of our
products or practices, as well as other risks discussed from time
to time in our filings with the Securities and Exchange Commission,
including, without limitation, our latest 10-Q Report filed on
January 17th, 2019. We undertake no duty to update any
forward-looking statement or any information contained in this
press release or in other public disclosures at any time. Finally,
the investing public is reminded that the only announcements or
information about Cannabics Pharmaceuticals Inc. which are condoned
by the Company must emanate from the Company itself and bear our
name as its Source.
For more information about
Cannabics:
Cannabics Pharmaceuticals Inc.
Phone: +1(877)424-2429
[email protected]
http://www.cannabics.com
View original content to download multimedia:http://www.prnewswire.com/news-releases/cannabics-pharmaceuticals-to-co-sponsor-the-canada-cannabis-house-at-the-world-economic-forum-in-davos-300781933.html